Jan Christian Wasmuth

Summary

Affiliation: University of Bonn
Country: Germany

Publications

  1. ncbi request reprint [Progressive multifocal leukoencephalopathy]
    J C Wasmuth
    Universitätsklinik Bonn
    Med Klin (Munich) 94:264-73. 1999
  2. ncbi request reprint Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma
    J C Wasmuth
    Department of Internal Medicine I, University Hospital of Bonn, Germany
    Eur J Med Res 13:483-6. 2008
  3. ncbi request reprint Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Eur J Med Res 12:289-94. 2007
  4. ncbi request reprint Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105, Bonn, Germany
    Eur J Clin Pharmacol 63:901-8. 2007
  5. ncbi request reprint [Splenic infarct in a patient with HIV infection]
    Jan Christian Wasmuth
    Medizinische Klinik und Poliklinik, Immunologische Ambulanz, Universitatsklinikum Bonn, Sigmund Freud Strasse 25, 53105 Bonn
    Med Klin (Munich) 100:683-5. 2005
  6. ncbi request reprint ROC analysis comparison of three assays for the detection of antibodies against double-stranded DNA in serum for the diagnosis of systemic lupus erythematosus
    Jan Christian Wasmuth
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Clin Chem 50:2169-71. 2004
  7. ncbi request reprint Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART
    Jan Christian Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Antiviral Res 61:207-12. 2004
  8. ncbi request reprint Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR)
    Jan Christian Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    Antivir Ther 9:213-20. 2004
  9. ncbi request reprint Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis
    J C Wasmuth
    Department of General Internal Medicine, University of Bonn, Germany
    J Acquir Immune Defic Syndr 23:44-51. 2000
  10. ncbi request reprint Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy
    J C Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    HIV Med 4:111-9. 2003

Detail Information

Publications23

  1. ncbi request reprint [Progressive multifocal leukoencephalopathy]
    J C Wasmuth
    Universitätsklinik Bonn
    Med Klin (Munich) 94:264-73. 1999
    ..TREATMENT: A specific therapy is not yet available or established. Highly active antiretroviral therapy (HAART) and cidofovir are promising and may prove useful in the near future...
  2. ncbi request reprint Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma
    J C Wasmuth
    Department of Internal Medicine I, University Hospital of Bonn, Germany
    Eur J Med Res 13:483-6. 2008
    ..The clinical spectrum ranges from asymptomatic hepatitis to fatal hepatic failure. Although it impairs the prognosis of cancer treatment, it may be overlooked due to other possible causes of liver damage...
  3. ncbi request reprint Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Eur J Med Res 12:289-94. 2007
    ..To compare two reduced dose indinavir (IDV) + ritonavir (RTV) combinations guided by therapeutic drug monitoring (TDM) in treatment-naive HIV1-infected patients...
  4. ncbi request reprint Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105, Bonn, Germany
    Eur J Clin Pharmacol 63:901-8. 2007
    ..We tested whether dose reduction of IDV guided by therapeutic drug monitoring resulted in improved tolerability without compromising antiviral efficacy...
  5. ncbi request reprint [Splenic infarct in a patient with HIV infection]
    Jan Christian Wasmuth
    Medizinische Klinik und Poliklinik, Immunologische Ambulanz, Universitatsklinikum Bonn, Sigmund Freud Strasse 25, 53105 Bonn
    Med Klin (Munich) 100:683-5. 2005
  6. ncbi request reprint ROC analysis comparison of three assays for the detection of antibodies against double-stranded DNA in serum for the diagnosis of systemic lupus erythematosus
    Jan Christian Wasmuth
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Clin Chem 50:2169-71. 2004
  7. ncbi request reprint Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART
    Jan Christian Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Antiviral Res 61:207-12. 2004
    ..A moderate decrease of RANTES was observed in both treatment groups. The data suggest that HAART regimens containing either NNRTI or PI are not equivalent with regard to modification of CC chemokine mRNA profiles...
  8. ncbi request reprint Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR)
    Jan Christian Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    Antivir Ther 9:213-20. 2004
    ..To assess the pharmacokinetics and tolerability of reduced dosages of twice daily indinavir (IDV) boosted by low-dose ritonavir (RTV) in healthy volunteers...
  9. ncbi request reprint Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis
    J C Wasmuth
    Department of General Internal Medicine, University of Bonn, Germany
    J Acquir Immune Defic Syndr 23:44-51. 2000
    ..The aim of the study was to compare accepted surrogate markers of HIV disease progression with markers of lymphocyte apoptosis in their ability to predict short-term disease progression...
  10. ncbi request reprint Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy
    J C Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    HIV Med 4:111-9. 2003
    ..To assess the effect of highly active antiretroviral therapy (HAART) on surrogate markers of lymphocyte apoptosis in HIV 1-infected individuals...
  11. ncbi request reprint Enteric dysfunction in patients with asymptomatic HIV-infection versus patients with hypoproteinemia/hypalbuminemia and advanced HIV-infection
    J C Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    Eur J Med Res 7:536-42. 2002
    ..It is unclear whether enteric dysfunction and protein losses contribute to hypoproteinemia, which heralds poor survival in HIV infection...
  12. ncbi request reprint Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks
    Jan Christian Wasmuth
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    AIDS 16:1077-8. 2002
  13. ncbi request reprint Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
    M Lichterfeld
    Department of General Internal Medicine, University of Bonn, Berlin, Germany
    HIV Med 3:37-43. 2002
    ....
  14. ncbi request reprint First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results
    E Voigt
    Department of Internal Medicine I, University of Bonn, Germany
    HIV Med 3:277-82. 2002
    ..To evaluate safety and efficacy of the protease inhibitor combination ritonavir/indinavir 100/800 mg twice daily plus 2-3 nucleoside reverse transcriptase inhibitors (NRTI) in antiretroviral-naive patients...
  15. ncbi request reprint Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations
    Jan Christian Wasmuth
    Department of Internal Medicine I, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
    Clin Chem 48:1004-10. 2002
    ..We analyzed the diagnostic accuracies for the diagnosis of antiphospholipid syndrome (APS) of 23 antiphospholipid antibody (APL-Ab) assays targeted at different antigen preparations and immunoglobulin isotypes...
  16. doi request reprint Drug safety evaluation of maraviroc for the treatment of HIV infection
    Jan Christian Wasmuth
    Universitatsklinikum Bonn, Medical Department I, Sigmund Freud Str 25, 53105 Bonn, Germany
    Expert Opin Drug Saf 11:161-74. 2012
    ..Maraviroc is the only C-chemokine receptor 5 (CCR5) antagonist approved for the treatment of infection with HIV. This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection...
  17. ncbi request reprint Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis
    B Terjung
    Department of Internal Medicine I, University of Bonn, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
    Eur J Med Res 9:439-48. 2004
    ..Antineutrophil cytoplasmic antibodies (atypical p-ANCA) are detected at high prevalence in sera from patients with autoimmune hepatitis (AIH), but their diagnostic relevance for AIH has not been systematically evaluated so far...
  18. ncbi request reprint Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results
    E Voigt
    Department of Internal Medicine, University of Bonn, Sigmund Freud Str 25, D 53105, Bonn, Germany
    Infection 32:82-8. 2004
    ..Within this open-label, uncontrolled prospective trial we evaluated safety, efficacy and development of genotypic resistance under the new protease inhibitor lopinavir/ritonavir (LPV/r) in antiretroviral (ARV) HIV patients...
  19. doi request reprint Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Germany
    J Antimicrob Chemother 63:988-91. 2009
    ..This study was undertaken to assess the differences in the pharmacokinetics of nevirapine between patients with HIV/HCV coinfection and HIV infection that could explain higher rates of hepatotoxicity...
  20. ncbi request reprint Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease
    Christian Hoffmann
    II Department of Internal Medicine, University Hospital of Kiel, Kiel, Germany
    Br J Haematol 125:455-62. 2004
    ..6 months, whereas the median survival time in patients with HAART response was not reached (89% OS at 24 months). In this cohort, a significant improvement in survival was found in patients with HIV-HD who responded to HAART...
  21. ncbi request reprint Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands
    Antivir Ther 8:309-14. 2003
    ..High indinavir Cmax values have been associated with indinavir-related nephrotoxicity...
  22. ncbi request reprint Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy
    Charles J L la Porte
    Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands
    AIDS 17:1700-2. 2003
    ..The tolerability of the regimen was good and efficacy was encouraging...